PTC Therapeutics, Inc. (PTCT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.93-0.05 (-0.63%)
At close: 4:00 PM EDT
People also watch:
ESPRAGIOPTLACMRXCLVS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open8.04
Prev Close7.98
Bid7.00 x 1800
Ask8.29 x 200
Day's Range7.73 - 8.47
52wk Range5.27 - 42.00
1y Target EstN/A
Market Cap270.28M
P/E Ratio (ttm)-1.54
Beta0.69
Volume1,014,750
Avg Vol (3m)1,055,817
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube13 hours ago

    ETF’s with exposure to PTC Therapeutics, Inc. : August 25, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to PTC Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to PTCT-US. Comparing the performance and risk of PTC Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube13 days ago

    ETF’s with exposure to PTC Therapeutics, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to PTC Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to PTCT-US. Comparing the performance and risk of PTC Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
    Capital Cube14 days ago

    PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

    Categories: Yahoo Finance Click here to see latest analysis PTC Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of PTC Therapeutics, Inc. – Vertex Pharmaceuticals Incorporated, Retrophin, Inc., Sarepta Therapeutics, Inc., Fate Therapeutics, Inc., Xencor, Inc. and Novartis AG Sponsored ADR (VRTX-US, RTRX-US, SRPT-US, FATE-US, ... Read more (Read more...)